Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neu-REFIX beta glucan is an orally consumable, allergen-free food supplement in gel form, developed by GN Corporation in Japan. The active ingredient is a beta-1,3-1,6-glucan exo-polysaccharide produced by the N-163 strain of *Aureobasidium pullulans* yeast. It functions as a biological response modifier glucan (BRMG), acting as a pathogen-associated molecular pattern (PAMP) to trigger immune responses through pattern recognition receptors like Dectin-1 and complement receptor 3 (CR3). [4] It is primarily being investigated for Duchenne muscular dystrophy (DMD), where it has demonstrated anti-inflammatory, anti-fibrotic, and muscle regeneration properties in preclinical models and clinical studies. [1, 2] The product has received Rare Pediatric Disease and Orphan Drug Designations from the US FDA for DMD. [1, 7, 10] Research has also explored its potential in other conditions, including multiple sclerosis, non-alcoholic steatohepatitis (NASH), COVID-19, and psoriasis vulgaris. [4, 11, 12] It has been commercially available in Japan as a food supplement since 2018. [1, 8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neu-REFIX beta glucan.